Connect with us


How The NSA hacks your devices

“It’s not as bad as you thought – it’s much worse.”

A leaked NSA cyber-arms catalog has shed light on the technologies US and UK spies use to infiltrate and remotely control PCs, routers, firewalls, phones and software from some of the biggest names in IT.

The exploits, often delivered via the web, provide clandestine backdoor access across networks, allowing the intelligence services to carry out man-in-the-middle attacks that conventional security software has no chance of stopping.

And if that fails, agents can simply intercept your hardware deliveries from Amazon to install hidden gadgets that rat you out via radio communications.

Continue reading.



The history of the clan who addicted the United States to drugs

A serious opioid crisis is brewing in the United States and is already recognized as a national problem. 142 people die here every day from an overdose of opioids. Many become addicted and addicted to prescription pain relievers. One of the most popular is OxyContin, manufactured by Purdue Pharma. It is owned by the Sackler family, renowned philanthropists and art trustees. We figure out how they managed to amass a multibillion-dollar fortune and hook the whole country on “legal drugs”.

On February 9, 2019, the famous American photo artist Nan Goldin held a protest in the Guggenheim, one of the most popular museums in New York, where, among other things, her work is exhibited.

On Saturday night, Goldin and activists from her PAIN (Prescription Addiction Intervention Now) movement walked into the museum and dropped a stack of prescription flyers for 80-milligram OxyContin tablets from the top floor. There were different quotes on them, for example, one of them: “If you do not control the use of OxyContin, then with a high degree of probability it will cause addiction. So how much will our sales grow? “

OxyContin is a popular prescription opioid pain reliever in the United States that is twice the strength of morphine. It is produced by Purdue Pharma, owned by the Sacklers, one of the wealthiest American families. Since 1996, when the drug went on sale, more than 200 thousand people have died from overdoses in the United States.

Of course, not all deaths are associated with OxyContin or other pain relievers – many of the victims, starting with opioids, switched to other drugs – for example, heroin. But it was Sackler’s Purdue Pharma that “destigmatized” the use of opioids in medicine and took the lead in the long-acting pain reliever market.

Three years ago, the doctor prescribed Nan Goldin OxyContin. She took the drug strictly according to the prescription, but soon could not do without it, increasing the dose and switching to drugs. It took ten months to free myself from the addiction. After that, she declared “war” on the Sackler family and decided at all costs to ensure that they were brought to justice.

“When I got out of treatment, I learned about drug addicts who were dying from my medicine, OxyContin. I learned that the Sacklers, whose surname I know from museums and galleries, is responsible for these deaths. This family invented, advertised and supplied OxyContin. I decided to bring them out of the shadows and bring them to justice, ”says Goldin’s petition on

We will tell you what the business of the Sackler family is like, how they managed to build an empire based on pain, and why clouds are gathering around them now.


Family business

Once upon a time there were three brothers – Arthur, Mortimer and Raymond. Descendants of Jewish immigrants, they grew up in Brooklyn during the Great Depression and quickly discovered not only a talent for medicine, but also a strong entrepreneurial grip.

Arthur began his career as a copywriter for an agency that specialized in advertising medical products. As The New Yorker notes, he showed Don Draper’s flair for marketing – he soon became the owner of the agency and revolutionized the drug promotion industry.

Arthur Sackler realized that advertising should be directed not only to patients, but also to doctors, so he began to place ads in specialized medical journals and publications. Realizing that physicians are influenced by colleagues, he won over the most influential of them to leave positive reviews on his product. In parallel with the advertising business, Sackler began publishing the Medical Tribune newspaper, whose audience was about 600 thousand doctors.

Arthur Sackler was not shy about any methods: in the 1950s, he released an advertisement for the new antibiotic Sigmamycin, which was accompanied by pictures of doctors’ business cards and the caption: “More and more doctors are choosing Sigmamycin as therapy.”

In 1959, an investigative reporter for The Saturday Review tried to contact some of the doctors whose names were in the advertisements and found out that they never existed. It is also known that he paid $ 300 thousand to the head of one of the departments of the Food and Drug Administration (FDA) Henry Welch so that he could, for example, casually mention the names of certain medicines in his speeches.

In 1952, Arthur and his brothers bought out Purdue Frederic, a company that researched, developed and licensed drugs and health products.

At the same time, Arthur Sackler became the first advertiser in history who managed to convince the editorial staff of the Journal of the American Medical Association (the weekly international medical scientific journal, the most read medical journal in the world. – Esquire) to include in one of the issues a color advertising brochure.

In the 1960s, the pharmaceutical company Roche hired Arthur to develop a marketing strategy for a new tranquilizer, Valium. It was not an easy task because the drug worked in much the same way as Librium, another Roche product already on the market.

And here’s what Sackler came up with: Unlike Librium, which was prescribed as a remedy for anxiety and anxiety, he decided to position Valium as a cure for “emotional stress”, which, according to advertising, was the true cause of a number of diseases – heartburn, diseases related to with problems with the gastrointestinal tract, insomnia, restless legs syndrome.

The campaign was such a success that Valium became America’s # 1 prescription drug and Arthur Sackler became one of the first Americans to enter the Medical Advertising Hall of Fame.

Arthur Sackler

One of the first of its own developments Purdue Frederic, which became interested in the American authorities, was a drug against high cholesterol, which had many side effects, including hair loss. In the early 1960s, Tennessee Senator Estes Kefover, who headed the subcommittee responsible for the pharmaceutical industry, became interested in the brothers’ activities.

In his notes, he wrote: “The Sackler empire is a full-cycle production – they can develop a new drug at their facility, conduct clinical testing and receive positive feedback from the hospitals with which they cooperate.

They design an advertising campaign and promote their product by publishing articles in medical newspapers and magazines that they own or have connections with. ” In January 1962, Arthur Sackler was summoned to Washington to testify, but not a single senator was able to offend him or convict him of lying – the businessman was ready for any questions and answered them sharply and confidently.

When asked if he knew about the side effects of the drug, he calmly stated: “Better to have thin hair, so thick coronary arteries.”

In May 1987, Arthur Sackler died of a heart attack, and his brothers Mortimer and Raymond bought his stake in Purdue Frederic for $ 22.4 million. The company was subsequently renamed Purdue Pharma and moved to Connecticut.

The branch of the family tree that goes from Arthur Sackler has since split from the heirs of Mortimer and Raymond and did not take part in the management of the company. Arthur’s daughter Elisaber Sackler, a feminist art historian and one of the trustees of the Brooklyn Museum, in her interviews firmly distanced herself from Purdue Pharma and called her relatives’ firm “morally disgusting.”

She even spoke publicly in support of Nan Goldin: “I admire Nan Goldin’s courage and her drive to make a difference. My father, Arthur M. Sackler, died in 1987, even before OxyContin, and his interest in Purdue Frederick was sold to the brothers a few months later.

None of his direct descendants have ever owned Purdue shares or benefited from the sale of OxyContin. I share the anger of those who oppose the abuse of power that harm or endanger people’s lives. “

Liz O. Baylen / Los Angeles Times via Getty Images

Empire of Pain

In the 1970s, opioids were not used in medicine in the United States, and so-called “opioidophobia” existed among doctors. There was a war in Vietnam, soldiers en masse were addicted first to soft drugs, then to opioids, and then to heroin, which they began to produce clandestinely.

After the end of the war, the soldiers returned to their homeland, and the United States faced a real heroin epidemic. Despite the stigmatization of opioids, opioid-based pain relievers have been widely used in hospice services to care for dying patients.

A turning point in Purdue’s history came when a London physician working for Cecil Saunders (a celebrated British nurse and social worker, considered the founder of the hospice movement) asked the company’s UK arm to develop a delayed-release morphine pill.

So in 1987, the innovative pain reliever MS-Contin appeared on the US market, which became a real hit in the treatment of cancer patients. At the same time, there was a discussion among the medical profession about the need to consider the use of opioids in the treatment of non-cancerous diseases, which can be equally debilitating for the patient.

Scientific articles have appeared that long-term opioid therapy is safe and effective if the patient does not have a history of drug addiction. The reputable New England Journal of Medicine even published an open letter in 1980 stating that the risk of addiction with long-term opioid use is less than 1%. The author then disavowed the material, but it was picked up by other specialized publications, and the theses from it were quoted more than 600 times.

Despite its popularity, MC-Contin could not become the pain reliever No. 1 – in large part due to the fact that there was some prejudice towards morphine. “People heard ‘morphine’ and said, hey, wait, I don’t seem to be dying,” Sally Allen Riddle, former managing director of product at Purdue, recalls in a conversation with Esquire. In addition, his patent was about to expire.

In a 1990 memorandum addressed to Richard Sackler and other top managers of the company, the company’s vice president of clinical research, Robert Kaiko, proposed the development of oxycodone, a substance similar to morphine, which was developed in 1916 by German scientists based on the opium poppy.

The advantage of this substance was that it was mistakenly considered weaker than morphine. Plus, inexpensive to manufacture, it has already been used in other drugs in combination with aspirin or paracetamol, which doctors have prescribed for severe injuries and injuries. “Oxycodone didn’t have the same negative connotation as morphine,” Riddle recalls.

Perdue Pharma has released pure oxycodone with a controlled release formula similar to MC-Continu. The company produced tablets in dosages of 10, 80 and 160 milligrams, which were stronger than any prescription opioid. Journalist and Pulitzer nominee Barry Meyer wrote in his book Pain Killer:

“In terms of drug power, Oxycontin was a nuclear weapon.”

In 1995, the FDA approved the use of OxyContin for moderate to severe pain. Purdue Pharma was allowed to label the packaging that the drug’s long-term exposure “diminishes” its attractiveness to drug addicts compared to other pain relievers (it was removed in 2001, and no opioid drug has been labeled this way since then).

Dr. Curtis Wright, who oversaw the FDA’s expertise, soon left the organization. Two years later, he went to work for the Sacklers. At a company meeting celebrating the launch of a new drug, Richard Sackler (son of Raymond Sackler) said, “The launch of OxyContin will be followed by a recipe blizzard that will bury the competition. She will be strong, dense and white. “

Jessica Hill / AP

Mortimer, Raymond and Richard Sackler took over Arthur’s marketing tactics and launched one of the largest advertising campaigns in pharmaceutical history. They have hired thousands of sales representatives, trained them and armed them with charts describing the benefits of the drug.

The company aimed to change the prevailing opinion among doctors that OxyContin should be prescribed only in cases of severe short-term pain in oncology and surgery, but also in cases of arthritis, back pain, injuries, and so on. One of the company’s managers, Stephen May, told The New Yorker that they had special trainings to “overcome doctors’ objections.”

At Purdue Pharma, they learned how to properly answer questions about possible drug abuse and convince professionals that it is virtually non-addictive.

Of course, no one took their word for it: the company paid thousands of medical practitioners to participate in various workshops (all costs covered) and report on the benefits of OxyContin.

Purdue approached the promotion from all angles: wholesalers received discounts, first-time pharmacists were reimbursed, patients received coupons for 30-day starter packs, academics received grants, medical journals received multimillion-dollar advertising, and members of Congress received generous donations.

Add to this massive advertising in professional publications and literature, advertisements with happy and satisfied patients on TV, and even specialized merchandise – fishing hats, plush toys, luggage tags, and so on.

It soon became known that Oxycontin was used as a drug. On the packaging of the product there was a warning about a possible narcotic effect: it said that if you inhale the powder from the crushed drug or inject it, it will lead to a rapid release of the drug and the absorption of a potentially toxic dose.

Some patients on prescriptions for OxyContin started selling the drug on the black market – at a price of one dollar per milligram.

In an interview with Esquire, Curtis Wright (the same FDA official who gave the green light to the prescription use of OxyContin) said that the drug use of OxyContin came as a shock to everyone: … It wasn’t Perdue’s invention, it wasn’t a secret plan or a clever marketing ploy. Chronic pain is terrible. When used correctly, opioid therapy is nothing short of a miracle; we brought people back to life. “

Between 1996 and 2001, the number of prescriptions for OxyContin in the United States grew from 300,000 to nearly six million – and the drug began to bring Purdue Pharma $ 1 billion a year. And in 2016, Forbes estimated the Sackler family’s fortune at $ 13 billion. This is just a rough figure: Purdue Pharma does not disclose its details. In the ranking of the richest American families, the Sacklers overtake the Rockefellers.

Temple of Dendur at the Metropolitan Museum, Sackler Wing

And here comes Guggenheim

The Sackler family are great philanthropists, they sponsor dozens of museums around the world, fund various scientific and research programs, universities and other institutions. “Unlike Andrew Carnegie, who has built hundreds of libraries in small towns, and Bill Gates, whose foundation serves the world, the Sacklers have woven their name into a patronage network of the world’s most prestigious and wealthy institutions.

The name Sackler is everywhere – and automatically evokes reverence. At the same time, the Sacklers themselves are almost invisible, ”wrote the American Esquire.

The courtyard of the Victoria and Albert Museum in London was reopened in the summer of 2017 after extensive renovation. The space of six tennis courts is decorated with a mosaic of 11 thousand porcelain tiles, handcrafted by the oldest Dutch company Koninklijke Tichelaar Makkum.

The courtyard is now known as the Sackler Courtyard – the museum does not disclose information about its donors, so it is not known for certain how much the family donated to V&A. Duchess of Cambridge Kate Middleton attended the grand opening of the courtyard. Stepping onto the shiny ceramic surface, she just said, “Wow,” recalls Esquire.

The Sackler family’s portfolio is not limited to the Victoria and Albert Museum.

Here are just some of the cultural institutions to which they are related: an entire wing in the New York Metropolitan Museum is named after them – it contains a grandiose artifact of ancient Egypt, the Dendur Temple, saved during the construction of a power plant on the Nile.

There is a Sackler wing in the Louvre and the British Royal Academy of Arts, its own museums – at Harvard and the University of Beijing, the Arthur Sackler Gallery – at the Smithsonian Institution in Washington, the Sackler Center at the Guggenheim Museum in New York, and an educational laboratory at the Natural History Museum in Manhattan … Family members are known in museum circles for giving projects their names, Esquire notes.

In 1974, when Arthur and his brothers made a $ 3.5 million donation to the Metropolitan Museum, they carefully prescribed that every sign, catalog and newsletter entry in the Sackler wing, included the names of all three brothers, with the MD subscript.

One of the museum officials even sarcastically: “It only remained to indicate their working schedule.” More modest projects have also received the Sackler name: for example, the Sackler Staircase at the Jewish Museum in Berlin, the Sackler escalator at the Tate Modern, the Sackler Crossroads at the Royal Botanic Gardens Kew in southwest London. A variety of pink roses is even named after them. And an asteroid.

Duchess of Cambridge Kate Middleton
Duchess of Cambridge Kate Middleton at the opening of the Victoria and Albert Museum after a major renovation

Opioid crisis

According to the US Centers for Disease Control and Prevention (a federal agency within the US Department of Health), 53,000 Americans died from opioid overdose in 2016.

The Opioid Crisis Commission, established by Donald Trump, cited an even more shocking figure of 64,000 – more than the total number of deaths from car accidents and from violence with firearms.

According to the commission, 142 people die daily from opioid overdose – as if 9/11 happened every three weeks. The opioid crisis has already been designated a health emergency. According to the medical publication STAT, if urgent measures are not taken, then about 500 thousand people can die from an overdose of opioids in the United States in the next 10 years.

Before the crisis entered its dangerous phase, the total economic burden of the state from opioid addicts was about $ 80 billion, including costs of health care and criminal justice.

Why the Sacklers are in trouble

Purdue Pharma has been repeatedly prosecuted in court, but for a long time the company has managed to avoid real liability. It was only in 2007 that the company admitted in a criminal proceeding that it had used doctors’ misconceptions about the potency of oxycodone to its advantage.

The materials said that the company “was well aware that the belief of doctors that oxycodone is weaker than morphine is wrong” and “did not want to take any action on this matter.” In accordance with the agreement reached, Purdue Pharma paid $ 600 million in fines, and three top managers of the company pleaded guilty and were sentenced to multimillion-dollar fines and community service.

At the same time, not a single Sackler figured in the lawsuit, despite the fact that Richard Sackler led the company during the most active period of promotion of OxyContin. This may now be changing: Last June, Massachusetts attorney general Maura Haley sued Purdue Pharma, its top executives and eight members of the Sackler family.

The state’s lawsuit contains dozens of internal documents from Purdue Pharma, which concluded that the Sackler family was much more actively involved in the company’s affairs than it was alleged.

The Sacklers were aware that the company did not disclose to the authorities information about the use of OxyContin as a drug and its sale on the black market, according to the lawsuit. Purdue Pharma also aggressively promoted the product in order to increase sales – in particular, through the use of discount cards for pharmacies.

Richard Sackler, who served as president of Purdue Pharma from 1999 to 2003, is named in court documents as the man responsible for all key decisions to promote OxyContin and to cover up drug abuse.

In particular, when Richard Sackler became aware of the 59 deaths from an OxyContin overdose in Massachusetts, he did not attach much importance to this: “It’s not that bad. It could have been much worse, ”he wrote to his subordinates.

However, as Esquire notes, the Sacklers are very likely to get off the water: in the agreement to waiver of prosecution, which the company entered into in 2007, paying a huge fine, the new charges will mainly relate to the company’s activities after 2007. Neither Richard Sackler nor other family members have held senior management positions at Purdue Pharma since 2003.

The company claims that the number of prescriptions for OxyContin dropped by 33% from 2012 to 2016, but at the same time it is expanding into the international market.

Investigation by The Los Angeles Times says Purdue is promoting OxyContin in Mexico, Brazil and China using the same marketing strategies: organizing panels and discussions on chronic pain, paying speakers to talk about the drug as an effective pain reliever, citing horrific numbers about the millions of people suffering from “silent pain”.

Following an investigation by The Los Angeles Times in May 2017, a number of congressmen sent a letter to the World Health Organization stating that the Sackler-owned companies were preparing to flood foreign countries with legal drugs.

Continue Reading


Will the bosses be able to track our thoughts at work?

Emotiv sensors, similar to headphones, can distinguish between brain waves that indicate a person’s stress or inattention. New technology is seen by people as another form of control over a person in his workplace.

The MN8 electroencephalography device looks like a sleek wireless headphone that can be worn all day without physical discomfort. In doing so, the device constantly monitors a person’s brain waves to identify levels of stress, focus and attention. So companies can collect data on the brain activity of their employees and draw appropriate conclusions.

Emotiv says the MN8 can create safe and efficient workplaces by tracking employee brain signals and then using the data for time management and other tasks related to work efficiency. It should be noted that the company is actively promoting a new product. In particular, at a forum sponsored by Fortune magazine and among the wealthy at the World Economic Forum in Davos.

Emotiv MN8


Oliver Oullier, neuroscientist and president of Emotiv, says the data has allowed companies to adjust work schedules and reallocate tasks that require increased attention, as well as improve the learning process. In addition, they began to start working in companies later, as it turned out that morning overload increases stress.

“We provide hardware and algorithmic solutions that have long been used in programs that have allowed people to work less, reduce absenteeism, reduce accidents and improve productivity,” Oullier wrote in an email to Motherboard.

The devices use electrodes – small metal discs that interact with brain cells when placed on the head, capturing various types of electromagnetic waves that are associated with attention and alertness.

Emotiv claims that all of the company’s customers sign an agreement that they will not promote, demote, punish or fire employees based on brain data. The companies that have used MN8 are not named, but are reported to be in the healthcare, information technology, automotive and transportation industries.

Continue Reading


Transhumanism: An implantable biochip for detecting COVID-19 could hit the markets by 2021

Like gravity, which was unknown before Newton, although it was in plain sight, there has been a scientific discovery for many years with a huge, colossal destructive potential for humanity. This potential is so immense that the largest war machine on the planet immediately used its resources to seize this discovery and gain complete control over it.

In 2010, Canadian scientist Derek Rossi unexpectedly and accidentally made a revolutionary breakthrough: he  found a way to “reprogram” molecules that carry genetic instructions for the development of cells in the human body, not to mention all other biological life forms.

The molecules in question are called “messenger ribonucleic acid” or mRNA. The newly acquired ability to rewrite instructions in these molecules has radically changed the course of Western medicine and science, but most surprisingly, no one but DARPA barely noticed. Meanwhile, in an interview about his discovery, Derek Rossi said: 

“The real important discovery here was that from now on you can use mRNA as you see fit. Now, if you put it in cells, then you can make mRNA express any protein in cells, which is a huge scientific achievement. “

Derek Rossi

The achievement was really so great that in 2014 Rossi, despite the fact that he was the founder of his own company Moderna Inc., was honorably retired and is now following his invention as a “hockey daddy”. This happened, apparently, because immediately after the miraculous discovery of Rossi, Moderna Inc., together with an obscure private investment company Flagship Pioneering, attracted almost half a billion dollars in federal money, which went to the development of vaccines based on the new technology. Probably, Dr. Rossi is now terrified, although he is now far from the first to be terrified and will not be alone. 

It all started with the fact that back in 2006, DARPA initiated the PHD program – the program for the identification of viral pathogens of the upper respiratory tract, the full name is Predicting Health and Disease (  PHD), which led to the creation of a separate BTO Office in DARPA DARPA – DARPA Biological Technologies Office (BTO). And in 2014, BTO DARPA launched its IVN program (In Vivo Nanoplatforms), which can be translated as “living nanoplatform” or, more precisely, “nanoplatform working in a living cell”. This is how a new miracle of biology and medicine appeared, which is called “hydrogel”.

Hydrogel is a nanotechnology whose inventor boasted that “if [it] can be implemented, with FDA approval , consumers will be able to implant intracellular sensors to measure glucose, oxygen and lactate levels.” … The new material, similar to contact lenses, requires a special injector to be inserted under the skin, after which it can transmit light digital signals over a wireless network such as 5G.

And then there were only two inventions left to add: mRNA controlling the behavior of the organism and the very same hydrogel as a substrate carrying mRNA . Together, both inventions open up a  nightmare of possibilities. Perhaps this is the first real step towards full-fledged transhumanism.

Transhumanism is a philosophical concept, as well as an international movement that supports the use of the achievements of science and technology to improve the mental and physical capabilities of a person in order to eliminate those aspects of human existence that transhumanists consider undesirable – suffering, disease, aging and death. Transhumanists study the possibilities and consequences of using such technologies, the dangers and benefits of their use, including the idea of ​​convergence of biological, information, cognitive and nanotechnologies.

This is how a new private company came into being, specifically set up to promote this combined technology that allows remote control of biological processes and opens the door to the potential manipulation of our biological responses. It is called Profusa Inc  and its operations are funded by the millions from the NIH ( US National Institutes of Health )  and DARPA (Defense Advanced Research Projects Agency).  And already in March 2020 Profusa Inc. unbeknownst to everyone, it was at the top of the crowded COVID-19 market, where it announced an injection biochip for the detection of viral respiratory diseases, including COVID-19. 

At the moment, the most promising vaccine against COVID-19 is mRNA-1273, which belongs to Moderna Inc. However, Moderna Inc. Is, in fact, a company created  with DARPA money. The brainchild from DARPA / Moderna Inc -Profusa promoting its miracle biochip to the market. At the same time, the only obstacle for the mRNA-1273 vaccine today is the delivery system of the desired mRNA into cells.

Somehow and so miraculously, a subsidiary of Profusa, also funded by DARPA, simultaneously with the development of a vaccine by other companies, is launching on the market biochips based on hydrogel and photosensitive sensors, which are expected to receive accelerated approval from the Office of Sanitary Inspection of Quality Food and Drug Administration by early 2021. In this case, it is obvious and most likely that Moderna Inc. will choose exactly its brainchild as a platform for the deployment of the coronavirus vaccine. But this platform, judging by what Dr. Rossi said, is capable of not only delivering mRNA to cells, but also remotely changing our DNA. 

Continue Reading